Language:English
Language:

Xcessbio

Place your promotion here

You have no items in your shopping cart.

FG-4592 (Roxadustat), HIF Prolyl-Hydroxylases Inhibitor

FG-4592 (Roxadustat), HIF Prolyl-Hydroxylases Inhibitor

$39.00
A potent, selective and bioavailable inhibitor of hypoxia-inducible factor prolyl hydroxylase.
Catalog No. Unit Price Qty
M60263-2s 2 mg solid $39.00

Details

Product Information
Molecular Weight: 352.34
Formula: C19H16N2O5
Purity: ≥98%
CAS#: 808118-40-3
Solubility: DMSO up to 50 mM
Chemical Name: (4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)glycine
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

FG-4592 (Roxadustat) is a potent, selective and bioavailable inhibitor of hypoxia-inducible factor prolyl hydroxylase. It is an analog of 2-oxoglutarate (2-OG) to inhibit HIF-PH and prevent HIF turnover. While little has been published regarding the actions of this compound, similar HIF-PH inhibitors suppress HIF degradation and in this way induce erythropoietin expression, promoting erythropoiesis or preventing anemia in vivo. Right now FG-4592 is in phase III clinical trials to treat anemia.

How to Use:


In vitro: FG-4592 was usually used at 10 µM final concentration in vitro.
In vivo: n/a

Reference:

  • 1. Hsieh MM, et al. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. (2007) Blood. 15;110(6):2140-7. 


FG-4592_spec.pdf     
FG-4592_MSDS.pdf 

Products are for research use only. Not for human use. 

Description

Details

Product Information
Molecular Weight: 352.34
Formula: C19H16N2O5
Purity: ≥98%
CAS#: 808118-40-3
Solubility: DMSO up to 50 mM
Chemical Name: (4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)glycine
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

FG-4592 (Roxadustat) is a potent, selective and bioavailable inhibitor of hypoxia-inducible factor prolyl hydroxylase. It is an analog of 2-oxoglutarate (2-OG) to inhibit HIF-PH and prevent HIF turnover. While little has been published regarding the actions of this compound, similar HIF-PH inhibitors suppress HIF degradation and in this way induce erythropoietin expression, promoting erythropoiesis or preventing anemia in vivo. Right now FG-4592 is in phase III clinical trials to treat anemia.

How to Use:


In vitro: FG-4592 was usually used at 10 µM final concentration in vitro.
In vivo: n/a

Reference:

  • 1. Hsieh MM, et al. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. (2007) Blood. 15;110(6):2140-7. 


FG-4592_spec.pdf     
FG-4592_MSDS.pdf 

Products are for research use only. Not for human use. 

Reviews

Write Your Review

How do you rate this product? *

Price:
Value:
Quality: